Peritoneal fibrosis and its prevention
Journal
Nephrology
Journal Volume
7
Journal Issue
5
Pages
227-232
Date Issued
2002
Author(s)
Abstract
Peritoneal fibrosing syndrome (PFS) is composed of a wide spectrum of peritoneal alterations observed in patients under peritoneal dialysis (PD). Long-term peritoneal exposure to unphysiological PD solutions and recurrent bacterial peritonitis had been claimed as the most common causes predisposing to the development of PFS in a PD population. With the advances in molecular research, physicians and pathologists recognized that peritoneal injury and the accompanied accumulation of extracellular matrix (ECM) within the peritoneum are key events leading to PFS. Bioincompatible solution and it's related products, inflammatory mediators, growth factors as well as cytokines in the peritoneal cavity are contributing factors. Therapeutic strategies antagonizing these mediators and/or their downstream intracellular signalling pathways with either drug molecules or gene transfer may have potential for the prevention or treatment of PFS.
SDGs
Other Subjects
antifibrotic agent; antiinflammatory agent; autacoid; collagen type 1; collagen type 2; corticosteroid; cytokine; dipyridamole; growth factor; immunosuppressive agent; messenger RNA; mitogen activated protein kinase; octreotide; Smad protein; tamoxifen; transforming growth factor beta; bacterial peritonitis; clinical research; concentration response; cytokine production; disease predisposition; drug effect; drug mechanism; extracellular matrix; gene transfer; histopathology; human; kidney fibrosis; nonhuman; pathogenesis; peritoneal cavity; peritoneal dialysis; priority journal; protein expression; review; signal transduction
Type
review